Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
QGEN Interest Income
Income earned on cash, deposits, and investments held by the company.
Qiagen N.V.NYSE: QGEN
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income declines year over year
Q2 FY2026 interest income of $9.36M fell 32.5% year over year, behind the -12.1% change in trailing-twelve-month interest income. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.
Context
- Interest income amounted to 3.1% of revenue in FY2025, down 0.4 pp from a year earlier.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -32.5% toward the trailing-twelve-month pace of -12.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 64.32M USD
- Year-over-year change
- -5.4%
- 4-year CAGR
- +61.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.32M | -5.4% |
| FY2024 | 2024-12-31 | 68.02M | -13.9% |
| FY2023 | 2023-12-31 | 78.99M | +141.1% |
| FY2022 | 2022-12-31 | 32.76M | +242.8% |
| FY2021 | 2021-12-31 | 9.56M | — |
Interest Income vs competitors
How QGEN compares with its peers on the latest reported figures
- QGEN's LTM Jun 2026 interest income of $54.99M is the 5th highest of the 11 companies compared; the peer median is $28.83M.
- Its year-over-year change of -12.1% is the 7th highest of 11, against a peer median of +2.9%.
- Interest income amounts to 2.6% of revenue for QGEN, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $950M | -1.1% | +54.0% | 2.0% | |
| LTM Sep 2026 | $132M | +325.8% | -9.9% | 0.5% | |
| LTM Jun 2026 | $88M | +6.9% | +18.1% | 3.4% | |
| LTM Jul 2026 | $60M | -13.0% | +90.3% | 0.8% | |
| LTM Jun 2026 | $54.99M | -12.1% | +25.2% | 2.6% | |
| LTM Jun 2026 | $33.43M | +147.8% | +58.1% | 4.3% | |
| LTM Jul 2026 | $24.24M | -52.5% | +105.4% | 0.8% | |
| LTM Jun 2026 | $20.72M | +7.0% | +117.2% | 9.9% | |
| LTM Sep 2026 | $20.32M | +18.3% | +44.5% | 3.3% | |
| LTM Jun 2026 | $4.9M | -52.4% | +74.2% | 0.1% | |
| LTM Sep 2026 | $985K | -74.9% | — | 0.1% | |
| Peer median (excluding QGEN) | $28.83M | +2.9% | +58.1% | 1.4% | |
Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Cost of Revenue | 800.84M | 756.96M | 731.62M | 1.01B | 798.5M |
| Gross Profit | 1.45B | 1.38B | 1.23B | 967.35M | 1.29B |
| Gross Margin | 64.4% | 64.7% | 62.8% | 48.9% | 61.8% |
| Research & Development | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| Selling, General & Admin | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| Operating Expenses | 820.74M | 853.1M | 823.75M | 869.64M | 771.19M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| EBITDA | 895.24M | 779.36M | 688.56M | 368.26M | 717.27M |
| EBITDA Margin | 39.8% | 36.4% | 35.0% | 18.6% | 34.3% |
| Operating Income | 630.08M | 531.46M | 409.94M | 97.71M | 520.31M |
| Operating Margin | 28.0% | 24.8% | 20.9% | 4.9% | 24.9% |
| Interest Income | 9.56M | 32.76M | 78.99M | 68.02M | 64.32M |
| Interest Expense | 54.48M | 58.36M | 53.41M | 43.84M | 33.26M |
| Other Income / Expenses | (4.25M) | (18.86M) | 19.87M | 23.44M | (30.04M) |
| Income Before Tax | 625.83M | 512.6M | 429.81M | 121.15M | 490.27M |
| Pre-Tax Margin | 27.8% | 23.9% | 21.9% | 6.1% | 23.5% |
| Income Tax Expense | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Net Margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (Basic) | 2.52 | 2.08 | 1.67 | 0.39 | 2.04 |
| EPS (Diluted) | 2.47 | 2.05 | 1.65 | 0.38 | 2.04 |
| Weighted Avg Shares | 221.14M | 220.75M | 217.49M | 216.44M | 207.94M |
| Weighted Avg Shares (Diluted) | 225.07M | 223.23M | 217.49M | 218.48M | 207.94M |
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.